Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

DBP International: Dossier for Inofer acquired

Read the release

In 2019 a clinical study was conducted in a collaboration between Double Bond Pharmaceutical AB ("Double Bond") and Skellefteå Lasarett. The study showed that iron succinate significantly improves iron uptake, iron saturation and iron storage in patients with heart failure and iron deficiency. Today, December 7 2020 Double Bond and Laboratorie X.O (France) signed an agreement for the acquisition and rights of Inofer[©]'s (iron succinate) registration dossier for the Nordic market.

"We are pleased with the positive clinical results of ferrous succinate's use. We strongly believe in the great market potential of the drug" - comments Igor Lokot, CEO at Double Bond - "The purchase of the dossier is the next important step for the development and marketing of the product on the Nordic market".

More about clinical study: https://mb.cision.com/Main/12720/2972792/1151388.pdf

More about Drugsson AB: www.drugsson.com

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team